Hologic (NASDAQ:HOLX) Price Target Raised to $68.00 at Evercore ISI

Hologic (NASDAQ:HOLX - Free Report) had its price objective increased by Evercore ISI from $62.00 to $68.00 in a report issued on Tuesday morning,Benzinga reports. They currently have an in-line rating on the medical equipment provider's stock.

Several other brokerages have also weighed in on HOLX. Wall Street Zen lowered shares of Hologic from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Stephens lowered their price target on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 13th. Raymond James Financial reiterated an "outperform" rating and issued a $71.00 price target (down from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Finally, Royal Bank Of Canada lowered their price target on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research report on Friday, May 2nd. Twelve research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $77.92.

Hologic Stock Performance

Shares of Hologic stock traded up $0.53 on Tuesday, reaching $64.90. 2,280,030 shares of the stock were exchanged, compared to its average volume of 2,376,341. The company has a current ratio of 3.24, a quick ratio of 2.52 and a debt-to-equity ratio of 0.54. The business has a fifty day moving average price of $60.84 and a two-hundred day moving average price of $63.60. Hologic has a 1-year low of $51.90 and a 1-year high of $84.67. The firm has a market capitalization of $14.46 billion, a PE ratio of 27.38, a PEG ratio of 2.37 and a beta of 0.55.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. During the same period in the prior year, the business posted $1.03 earnings per share. The firm's revenue for the quarter was down 1.2% compared to the same quarter last year. As a group, research analysts anticipate that Hologic will post 4.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Martin D. Madaus acquired 5,445 shares of the stock in a transaction on Wednesday, May 7th. The stock was bought at an average price of $55.24 per share, with a total value of $300,781.80. Following the completion of the transaction, the director directly owned 5,445 shares of the company's stock, valued at $300,781.80. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.88% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Hologic

Several large investors have recently modified their holdings of HOLX. Smartleaf Asset Management LLC lifted its holdings in Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after acquiring an additional 159 shares during the last quarter. Beverly Hills Private Wealth LLC lifted its holdings in Hologic by 3.6% in the first quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider's stock worth $320,000 after acquiring an additional 180 shares during the last quarter. Allworth Financial LP lifted its holdings in Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after acquiring an additional 216 shares during the last quarter. Dark Forest Capital Management LP lifted its holdings in Hologic by 7.9% in the fourth quarter. Dark Forest Capital Management LP now owns 3,053 shares of the medical equipment provider's stock worth $220,000 after acquiring an additional 223 shares during the last quarter. Finally, Baker Avenue Asset Management LP lifted its holdings in Hologic by 0.5% in the fourth quarter. Baker Avenue Asset Management LP now owns 42,051 shares of the medical equipment provider's stock worth $3,031,000 after acquiring an additional 225 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.